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OBJECTIVES: To evaluate and compare the performance of available disease-speciﬁc 
health-related quality of life (HRQL) instruments for use in heart failure. METHODS: 
A systematic review identiﬁed 5 disease-speciﬁc HRQL questionnaires for use in heart 
failure (Minnesota Living with Heart Failure questionnaire [MLHFQ], Chronic Heart 
Failure questionnaire [CHFQ], Kansas City Cardiomyopathy questionnaire [KCCQ], 
Left Ventricular Disease Questionnaire [LVDQ], and the Quality of Life in Severe 
Heart Failure Questionnaire [QLSHFQ]). The 5 questionnaires were evaluated using 
EMPRO (Evaluating Measures of Patient Reported Outcomes), a tool for the stan-
dardized assessment of the psychometric properties and usability of patient reported 
outcome measures. Groups of four expert appraisers evaluated 8 attributes for each 
instrument and gave an overall recommendation after a consensus procedure. Scores 
ranged from 0 (worst possible score) to 100 (best possible score). Inter-rater agreement 
(intra-class correlation coefﬁcient – ICC) was analyzed and median scores and ranges 
for all EMPRO attributes were calculated. An overall recommendation was provided 
(highly recommended, recommended with provisos, not recommended, unsure). 
RESULTS: Inter-rater agreement for EMPRO was generally acceptable (ICC of 0.48 
– 0.93 for individual attributes). Median overall EMPRO ratings and attribute score 
ranges were: MLHFQ (59.8, 33.3–69.4), CHFQ (54.9, 38.1–72.2), KCCQ (47.2, 
38.1–100), LVDQ (47.7, 11.1–76.7), and QLSHFQ (7.7, 5.6–26.6). The highest 
scores for all instruments except the QLSHFQ were on responsiveness (median scores 
from 5.6 to 100). Three of the questionnaires (MLHFQ, CHFQ, KCCQ) were recom-
mended with provisos; the LVDQ and QLSHFQ were not recommended. CONCLU-
SIONS: Of the 5 instruments evaluated, 2 (MLHFQ, CHFQ) scored well on EMPRO 
and were recommended, whilst the others may be limited to use in particular types of 
study or require further investigation. This type of assessment can provide useful 
information for questionnaire selection. Funding: This work was supported by grants 
from Instituto de Salud Carlos III FEDER, (PI08/90724).
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EXPLORING PATIENTS’ SATISFACTION WITH ANTICOAGULANT 
TREATMENT BY APPLYING STRUCTURAL EQUATION MODELS TO 
THE PERCEPTION OF ANTICOAGULANT TREATMENT 
QUESTIONNAIRE (PACT-Q)
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OBJECTIVES: To explore the process of patients’ satisfaction with anticoagulant         
treatment using Structural Equation Modeling (SEM). METHODS: The Perception  
of AntiCoagulant Treatment Questionnaire (PACT-Q) includes 2 modules: a 7-item 
module assessing patient expectations of anticoagulant treatment and a 20-item 
module assessing treatment convenience and patient satisfaction. It was completed by 
deep venous thrombosis, atrial ﬁbrillation and pulmonary embolism patients in 3 
clinical trials assessing anticoagulant treatments. The ﬁrst module was administered 
at baseline (BL) and the second after 3 (M3) and 6 months (M6). SEM was applied 
to pooled data from the three trials. SEM speciﬁcations were supported by the ques-
tionnaire conceptual model, satisfaction theory and the scoring rules of the instrument. 
The goodness of ﬁt of the models was assessed using a set of commonly used ﬁt indices 
including the Root Mean Square of Approximation (RMSEA). Association between 
latent variables was assessed using Standardized Path Coefﬁcients (SPC). RESULTS: 
A total of 986 patients had fully completed PACT-Q at BL, M3 and M6. PACT-Q 
items allowed good measurement of Convenience (RMSEA  0.054) and Satisfaction 
(RMSEA  0.028) at M3. The 7 expectation items were kept independent. An overall 
model involving two expectation items (expectations of symptom relief, worries about 
making mistakes) and both Satisfaction and Convenience at M3 and M6 was esti-
mated (RMSEA  0.032). In this ﬁnal model, Convenience had a stronger impact on 
Satisfaction at M3 than at M6 (respective SPC: 0.57 vs 0.48). Convenience at M6 was 
very strongly related with Convenience at M3 (SPC: 0.80) while the relationship 
between Satisfaction at M3 and M6 was weaker (SPC: 0.52). CONCLUSIONS: The 
application of SEM to the PACT-Q data allowed the prominent role of patients’ 
expectations and perception of treatment convenience in the process of anticoagulant 
treatment satisfaction to be highlighted. Convenience was also shown to be more 
stable over time than satisfaction.
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OBJECTIVES: To compare health-related quality-of-life (HRQoL) and resource use 
in patients with metabolic syndrome across three geographies. METHODS: Data used 
from the 2008 National Health and Wellness Survey (NHWS), an annual internet 
survey of adults in the US, EU (Germany, Spain, Italy, UK, and France), and 
Japan (JPN). Metabolic syndrome was deﬁned as having at least three of: diabetes, 
BMI  30, high cholesterol, or hypertension. Resource use included emergency room 
(ER) visits, hospitalizations, and visits to traditional health care providers. Linear 
regression was used to determine the effects of geography on the physical component 
summary score (PCS) and mental component summary score (MCS) of the SF-12, and 
Poisson regression for resource use, controlling for age, gender and total number of 
comorbidities. RESULTS: Of the 11,131 patients with metabolic syndrome 2,503, 
185 and 8,443 were from EU, JPN, and US, respectively. All prevalence numbers were 
signiﬁcantly different from one another (p  0.05). Mean MCS scores were 45.86, 
45.84, and 47.39 for EU, JPN and US, respectively, with a signiﬁcant difference 
between EU and US (p  0.05). The PCS score for JPN (44.86) was signiﬁcantly higher 
than both US (38.76) and EU (38.41) PCS scores (p  0.05). After controlling for 
confounders, JPN MCS scores were 2.87 points lower than the US (p  0.05), while 
EU scores were 2.09 points lower (p  0.05). JPN PCS scores were 4.92 points higher 
(p  0.05), and EU scores were 1.22 points lower than the US (p  0.05). The regres-
sion results for resource use showed JPN with fewer ER visits than US, and both JPN 
and EU with more hospitalizations, and more provider visits (p  0.05). CONCLU-
SIONS: There are signiﬁcant differences in prevalence and possibly awareness of 
metabolic syndrome across the three regions. Also, signiﬁcant differences were seen 
in both HRQoL and resource use. Further research is needed to describe the burden 
of metabolic syndrome globally.
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IMPACT OF HOSPITALIZATION ON HEALTH-RELATED QUALITY OF 
LIFE IN ATRIAL FIBRILLATION PATIENTS
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OBJECTIVES: Hospitalization is recognized as an important endpoint in atrial ﬁbril-
lation (AF) clinical trials. The association between hospitalization and reduced health-
related quality of life (HRQOL) has not been studied. Therefore, a large AF registry 
was used to characterize the impact of hospitalization on HRQOL. METHODS: The 
FRACTAL study was an observational registry of patients enrolled in the United States 
and Canada with new-onset AF. HRQOL was assessed with the SF-12 and the AF 
Symptom Checklist at baseline, 3, 6, and 12, 24 and 30 months. Mixed linear regres-
sion models were ﬁtted to estimate the impact of hospitalization on HRQOL summary 
scores (physical and mental component scores of SF-12, symptom frequency and 
severity, and utilities from the SF-12), adjusting for demographic and clinical variables 
known to inﬂuence HRQOL in this population. RESULTS: Of 933 subjects who 
completed HRQOL questionnaires and were not hospitalized during the baseline study 
visit, 303 (32%) were hospitalized a total of 490 times during an average of 2.0 years 
of follow-up. The majority (64%) of these admissions were for cardiovascular causes. 
The adjusted effect of any hospital admission (vs. none) on symptom frequency and 
severity scores over time was 1.3 and 1.1 points, respectively (p  0.01 for both), 
with higher scores indicating greater symptom burden. The adjusted effect of any 
admission on the SF-12 physical score was 2.7 points (p  0.0001) and a decrement 
on utility of 0.03 (p  0.0001). In contrast, hospitalization had little effect on longi-
tudinal SF-12 mental scores (0.7 points, p  0.15). CONCLUSIONS: In a real life 
long term AF registry, hospitalizations during follow-up were associated with signiﬁ-
cant increases in AF symptoms and decrements in generic physical HRQOL and utili-
ties. Based on these results which may be limited by the study design, interventions 
that reduce hospital admissions in AF patients would be expected to improve or 
 preserve HRQOL.
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OBJECTIVES: To assess whether the type of atrial ﬁbrillation (AF) could have a dif-            
ferent impact on patients’ HRQoL. METHODS: An observational, prospective, mul-   
ticentre study among 29 cardiologists specialized in arrhythmia, in the context of usual 
clinical practice was carried out to validate the AF-QoL questionnaire. AF patients 
(paroxysmal, persistent or permanent) were included. Variables recorded were age, 
NYHA scale, symptoms (number and frequency), emergency visits and AF-QoL score. 
RESULTS: A total of 341 AF patients were included (43% with persistent AF, 37%          
with paroxysmal AF and 20% with permanent AF). Paroxysmal AF patients were the 
youngest, with a mean age (SD) of 57(13) years, and reported better physical state, 
according to NYHA scale (67%, class I). Palpitations were the most prevalent 
symptom in paroxysmal AF patients (91%); dyspnea was the most prevalent symptom 
in persistent (70%) and permanent AF (77%). Paroxysmal AF patients reported the 
greatest number (4.5(2.5)) and frequency of symptoms (30% reported weekly symp-
toms), as well as the major number of emergency visits (2.2(1.7)) (p  0.05). Permanent 
AF patients showed better HRQoL in the psychological dimension of AF-QoL (47(28) 
points vs 38(26) and 37(26) in paroxysmal and persistent AF, respectively) (p  0.03). 
The rest of AF-QoL domains were similar between AF patients. The presence of 
symptoms was associated to a decrease in HRQoL in all AF patients, especially 
 palpitations in paroxysmal AF patients and palpitations, dyspnea and chest pain in 
permanent AF. Moreover, the more frequent the symptoms, the lower the AF-QoL 
score (p  0.05). A correlation was observed between the increase of emergency visits 
